GlaxoSmithKline (GSK) Earns “Buy” Rating from Shore Capital

Share on StockTwits

Shore Capital reiterated their buy rating on shares of GlaxoSmithKline (LON:GSK) in a research note released on Tuesday.

Other analysts have also issued research reports about the company. UBS Group set a GBX 1,600 ($20.71) price target on GlaxoSmithKline and gave the company a buy rating in a report on Friday, May 25th. Liberum Capital reiterated a buy rating on shares of GlaxoSmithKline in a report on Wednesday, May 16th. Jefferies Financial Group set a GBX 1,650 ($21.36) price target on GlaxoSmithKline and gave the company a buy rating in a report on Monday, May 14th. Berenberg Bank boosted their price target on GlaxoSmithKline from GBX 1,780 ($23.04) to GBX 1,790 ($23.17) and gave the company a buy rating in a report on Wednesday, April 25th. Finally, Goldman Sachs Group set a GBX 1,900 ($24.60) price target on GlaxoSmithKline and gave the company a buy rating in a report on Friday, June 29th. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and ten have assigned a buy rating to the company. The company presently has a consensus rating of Hold and an average target price of GBX 1,541.74 ($19.96).

Shares of GlaxoSmithKline opened at GBX 1,575.60 ($20.40) on Tuesday, according to MarketBeat Ratings. GlaxoSmithKline has a 52-week low of GBX 1,235.20 ($15.99) and a 52-week high of GBX 1,724.50 ($22.32).

The firm also recently declared a dividend, which will be paid on Thursday, October 11th. Stockholders of record on Thursday, August 9th will be given a dividend of GBX 19 ($0.25) per share. This represents a dividend yield of 1.23%. The ex-dividend date is Thursday, August 9th.

In other GlaxoSmithKline news, insider Philip R. Hampton purchased 2,810 shares of GlaxoSmithKline stock in a transaction dated Wednesday, July 25th. The shares were acquired at an average cost of GBX 1,557 ($20.16) per share, with a total value of £43,751.70 ($56,636.50). Also, insider David Redfern sold 1,925 shares of the company’s stock in a transaction on Tuesday, July 31st. The stock was sold at an average price of GBX 1,575 ($20.39), for a total value of £30,318.75 ($39,247.57).

About GlaxoSmithKline

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Further Reading: Marijuana Stocks Investing Considerations

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Just Energy Group Inc  Expected to Announce Earnings of $0.14 Per Share
Just Energy Group Inc Expected to Announce Earnings of $0.14 Per Share
Verge  Reaches 24-Hour Volume of $2.37 Million
Verge Reaches 24-Hour Volume of $2.37 Million
LeaCoin  Hits Market Cap of $49,810.00
LeaCoin Hits Market Cap of $49,810.00
Brokerages Set Darling Ingredients Inc  Target Price at $20.60
Brokerages Set Darling Ingredients Inc Target Price at $20.60
Elementis plc  Given Consensus Rating of “Buy” by Analysts
Elementis plc Given Consensus Rating of “Buy” by Analysts
Stellar  Hits Market Cap of $4.38 Billion
Stellar Hits Market Cap of $4.38 Billion


Leave a Reply

 
© 2006-2018 Zolmax.